Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma

We report a response to pazopanib in a 69-year-old man with heavily pre-treated metastatic extraosseous Ewing sarcoma in addition to molecular profiling of his tumor. To our knowledge, this case is the earliest to demonstrate activity of an oral multi-targeted kinase inhibitor in Ewing sarcoma. This case provides rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of regorafenib, another multi-targeted kinase inhibitor, in patients with liposarcoma, osteosarcoma and Ewing and Ewing-like sarcomas (NCT02048371). This national multi-institutional study is ongoing.

[1]  T. Alcindor.  Response of refractory Ewing sarcoma to pazopanib , 2015, Acta oncologica.

[2]  E. Kleinerman,et al.  Blocking SDF-1α/CXCR4 Downregulates PDGF-B and Inhibits Bone Marrow–Derived Pericyte Differentiation and Tumor Vascular Expansion in Ewing Tumors , 2013, Molecular Cancer Therapeutics.

[3]  R. Maki,et al.  A model for multi-institutional, multidisciplinary sarcoma videoconferencing. , 2013 .

[4]  Moritz A. Konerding,et al.  Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing’s sarcoma A673-xenograft growth and normalize tumor vascular architecture , 2012, Angiogenesis.

[5]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[6]  J. Neuhaus,et al.  Clinical features and outcomes in patients with extraskeletal ewing sarcoma , 2011, Cancer.

[7]  T. Choueiri,et al.  Pazopanib: Clinical development of a potent anti-angiogenic drug. , 2011, Critical reviews in oncology/hematology.

[8]  K. Glaser,et al.  ABT-869 Inhibits the Proliferation of Ewing Sarcoma Cells and Suppresses Platelet-Derived Growth Factor Receptor β and c-KIT Signaling Pathways , 2010, Molecular Cancer Therapeutics.

[9]  A. Craft,et al.  Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. D. de Jong,et al.  Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints , 1992, Genes, chromosomes & cancer.

[11]  R. Johnson,et al.  Past failures and future possibilities in Ewing's sarcoma: Experimental and preliminary clinical results , 1969, Cancer.